Acasti Pharma Inc ACST:NASDAQ

RT Quote | NASDAQ | USD
Last | 05/26/22 EDT
0.9223UNCH (UNCH)
Volume
86,825
52 week range
0.82 - 5.44
Loading...
  • Open0.94
  • Day High0.946
  • Day Low0.9035
  • Prev Close0.9189
  • 52 Week High5.44
  • 52 Week High Date06/23/21
  • 52 Week Low0.82
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap41.83M
  • Shares Out44.29M
  • 10 Day Average Volume0.19M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-26.8

KEY STATS

  • Open0.94
  • Day High0.946
  • Day Low0.9035
  • Prev Close0.9189
  • 52 Week High5.44
  • 52 Week High Date06/23/21
  • 52 Week Low0.82
  • 52 Week Low Date05/12/22
  • Market Cap41.83M
  • Shares Out44.29M
  • 10 Day Average Volume0.19M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-26.8

RATIOS/PROFITABILITY

  • EPS (TTM)-0.41
  • P/E (TTM)-2.22
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date06/20/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Acasti Pharma Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Acasti Pharma Inc. is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN). The Company's lead product candidate includes GTX-104, which is a clinical-stage nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. The Company's...
Roderick Carter
Independent Chairman of the Board
Janelle D'Alvise
President, Chief Executive Officer, Director
Pierre Lemieux Ph.D.
Chief Operating Officer, Chief Scientific Officer
Brian Ford CPA
Chief Financial Officer
Address
102-3009 boul. de la Concorde E
Laval, QC
H7E 2B5
Canada